Equivalent Steady-State Pharmacokinetics of Lamivudine in Plasma and Lamivudine Triphosphate within Cells following Administration of Lamivudine at 300 Milligrams Once Daily and 150 Milligrams Twice Daily
暂无分享,去创建一个
[1] S. Hammer,et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. , 2001, JAMA.
[2] Y. Lou,et al. Abacavir/Lamivudine/Zidovudme As a Combined Formulation Tablet: Bioequivalence Compared with Each Component Administered Concurrently and the Effect of Food on Absorption , 2001, Journal of clinical pharmacology.
[3] Jeff D. Moore,et al. Simultaneous quantitation of the 5′-triphosphate metabolites of zidovudine, lamivudine, and stavudine in peripheral mononuclear blood cells of HIV infected patients by high-performance liquid chromatography tandem mass spectrometry , 2000, Journal of the American Society for Mass Spectrometry.
[4] J. Bartlett,et al. Population Pharmacokinetics of Lamivudine in Adult Human Immunodeficiency Virus-Infected Patients Enrolled in Two Phase III Clinical Trials , 1999, Antimicrobial Agents and Chemotherapy.
[5] D. Back,et al. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. , 1999, AIDS.
[6] G. E. Pakes,et al. Lamivudine/Zidovudine as a Combined Formulation Tablet: Bioequivalence Compared with Lamivudine and Zidovudine Administered Concurrently and the Effect of Food on Absorption , 1999, Journal of clinical pharmacology.
[7] G. E. Pakes,et al. Clinical Pharmacokinetics of Lamivudine , 1999, Clinical pharmacokinetics.
[8] S. Staszewski,et al. Nevirapine/didanosine/lamivudine once daily in HIV-1-infected intravenous drug users. , 1998, Antiviral therapy.
[9] D. Back,et al. Lamivudine (3TC) phosphorylation and drug interactions in vitro. , 1997, Biochemical pharmacology.
[10] C. Perry,et al. Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. , 1997, Drugs.
[11] A. Breckenridge,et al. The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites , 1996, AIDS.
[12] J. Rodman,et al. A systemic and cellular model for zidovudine plasma concentrations and intracellular phosphorylation in patients. , 1996, The Journal of infectious diseases.
[13] D. Kuritzkes,et al. Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter , 1995 .
[14] R. Bethell,et al. The intracellular phosphorylation of (-)-2'-deoxy-3'-thiacytidine (3TC) and the incorporation of 3TC 5'-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase gamma. , 1995, Biochemical pharmacology.
[15] J. Montaner,et al. A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. , 1995, The Journal of infectious diseases.
[16] R. Tubiana,et al. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. , 1995, The Journal of infectious diseases.
[17] N. Beeching,et al. Zidovudine phosphorylation in HIV‐infected patients and seronegative volunteers , 1994, AIDS.
[18] J. Rodman,et al. Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells , 1994, Antimicrobial Agents and Chemotherapy.
[19] J. Cameron,et al. Cellular metabolism of (-) enantiomeric 2'-deoxy-3'-thiacytidine. , 1992, Biochemical pharmacology.
[20] J. Cameron,et al. The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro , 1992, Antimicrobial Agents and Chemotherapy.
[21] M. Wainberg,et al. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog , 1991, Antimicrobial Agents and Chemotherapy.